290 related articles for article (PubMed ID: 27495775)
21. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
El Chaer F; Mori N; Shah D; Oliver N; Wang E; Jan A; Doan V; Tverdek F; Tayar J; Ariza-Heredia E; Chemaly RF
Antiviral Res; 2016 Nov; 135():91-96. PubMed ID: 27594527
[TBL] [Abstract][Full Text] [Related]
23. [Clinical analysis of the efficacies of ganciclovir plus foscarnet and a single antiviral drug for the treatment of cytomegalovirus infection after haploidentical stem cell transplantation].
Ma R; He Y; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2023 Jan; 62(1):76-83. PubMed ID: 36631041
[No Abstract] [Full Text] [Related]
24. Resource Use and Financial Impact of Oral Step-Down Therapy for Resistant Cytomegalovirus in Solid Organ Transplant Recipients.
Kleiboeker H; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA; Jorgenson MR
Transplant Proc; 2024 Mar; 56(2):434-439. PubMed ID: 38355369
[TBL] [Abstract][Full Text] [Related]
25. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
[TBL] [Abstract][Full Text] [Related]
26. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Hebart H; Kanz L; Jahn G; Einsele H
Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
[TBL] [Abstract][Full Text] [Related]
27. Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia.
Chen J; Abella Ross J; Tegtmeier B; Yang D; Ito JI; Zaia JA; Dickter JK; Nakamura R; Mokhtari S; Kriengkauykiat J; Al Malki MM; Dadwal SS
Transpl Infect Dis; 2020 Apr; 22(2):e13233. PubMed ID: 31840347
[TBL] [Abstract][Full Text] [Related]
28. Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection.
Ouellette CP
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366468
[TBL] [Abstract][Full Text] [Related]
29. Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Spinner ML; Lam SW; Koval CE; Athans V
J Clin Virol; 2019 Nov; 120():12-16. PubMed ID: 31514101
[TBL] [Abstract][Full Text] [Related]
30. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.
Springer KL; Chou S; Li S; Giller RH; Quinones R; Shira JE; Weinberg A
J Clin Microbiol; 2005 Jan; 43(1):208-13. PubMed ID: 15634973
[TBL] [Abstract][Full Text] [Related]
31. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
32. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
[TBL] [Abstract][Full Text] [Related]
33. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.
Julin JE; van Burik JH; Krivit W; Webb C; Holman CJ; Clark HB; Balfour HH
Transpl Infect Dis; 2002 Dec; 4(4):201-6. PubMed ID: 12535263
[TBL] [Abstract][Full Text] [Related]
34. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Meesing A; Razonable RR
Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
[TBL] [Abstract][Full Text] [Related]
35. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
Bueno J; Ramil C; Green M
Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
[TBL] [Abstract][Full Text] [Related]
36. New Treatment Options for Refractory/Resistant CMV Infection.
Walti CS; Khanna N; Avery RK; Helanterä I
Transpl Int; 2023; 36():11785. PubMed ID: 37901297
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
[TBL] [Abstract][Full Text] [Related]
38. Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients.
Bonatti H; Sifri CD; Larcher C; Schneeberger S; Kotton C; Geltner C
Surg Infect (Larchmt); 2017; 18(2):128-136. PubMed ID: 27849440
[TBL] [Abstract][Full Text] [Related]
39. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
Isada CM; Yen-Lieberman B; Lurain NS; Schilz R; Kohn D; Longworth DL; Taege AJ; Mossad SB; Maurer J; Flechner SM; Mawhorter SD; Braun W; Gordon SM; Schmitt SK; Goldman M; Long J; Haug M; Avery RK
Transpl Infect Dis; 2002 Dec; 4(4):189-94. PubMed ID: 12535261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
